Edmond DE Rothschild Holding S.A. lifted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 29.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 146,320 shares of the company’s stock after buying an additional 33,000 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Ionis Pharmaceuticals were worth $6,533,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC boosted its stake in shares of Ionis Pharmaceuticals by 7.4% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 2,926 shares of the company’s stock worth $232,000 after acquiring an additional 202 shares in the last quarter. HighTower Advisors LLC grew its position in Ionis Pharmaceuticals by 7.6% in the 2nd quarter. HighTower Advisors LLC now owns 4,084 shares of the company’s stock worth $324,000 after purchasing an additional 287 shares during the last quarter. Grandfield & Dodd LLC raised its holdings in Ionis Pharmaceuticals by 0.9% in the 3rd quarter. Grandfield & Dodd LLC now owns 37,396 shares of the company’s stock valued at $1,670,000 after acquiring an additional 319 shares in the last quarter. North Dakota State Investment Board boosted its stake in Ionis Pharmaceuticals by 7.1% during the third quarter. North Dakota State Investment Board now owns 5,035 shares of the company’s stock worth $225,000 after buying an additional 332 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in Ionis Pharmaceuticals by 6.4% in the third quarter. ProShare Advisors LLC now owns 5,762 shares of the company’s stock valued at $257,000 after acquiring an additional 345 shares during the period. Hedge funds and other institutional investors own 93.86% of the company’s stock.
Ionis Pharmaceuticals Price Performance
Shares of NASDAQ:IONS opened at $26.58 on Friday. Ionis Pharmaceuticals, Inc. has a one year low of $26.53 and a one year high of $86.74. The company has a debt-to-equity ratio of 3.42, a current ratio of 5.43 and a quick ratio of 5.36. The company has a market cap of $4.43 billion, a price-to-earnings ratio of -8.01 and a beta of 0.43. The firm has a 50 day simple moving average of $40.76 and a 200 day simple moving average of $63.17.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The company had revenue of $242.72 million for the quarter, compared to analysts’ expectations of $178.17 million. During the same period in the previous year, the business posted ($0.80) earnings per share. The business’s quarterly revenue was up 54.8% compared to the same quarter last year. Research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.48 earnings per share for the current fiscal year.
Top Ionis Pharmaceuticals Stories
Here are a few of the latest stories about IONS:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $70 price target, despite lowering its earnings forecasts. Ionis analyst estimates
- Negative Sentiment: HC Wainwright lowered its earnings estimates across several periods. Its FY2027 loss estimate widened to $1.94 per share from $1.25, and it also cut estimates for Q4 2026 and Q1–Q3 2027. The downward revisions could reinforce concerns about Ionis’s path to profitability. Ionis analyst estimates
- Negative Sentiment: Guggenheim also cut its price target for Ionis, adding to the bearish analyst news; the report provided here does not specify the new target. Ionis Pharmaceuticals stock price target cut by Guggenheim
Insider Activity at Ionis Pharmaceuticals
In related news, EVP Shannon L. Devers sold 1,357 shares of the company’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total value of $59,083.78. Following the sale, the executive vice president owned 17,811 shares in the company, valued at $775,490.94. This represents a 7.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were bought at an average cost of $29.64 per share, with a total value of $148,200.00. Following the completion of the acquisition, the director directly owned 27,000 shares in the company, valued at approximately $800,280. This represents a 22.73% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 1.81% of the company’s stock.
Analyst Ratings Changes
Several brokerages recently issued reports on IONS. Oppenheimer cut their price target on shares of Ionis Pharmaceuticals from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Tuesday, November 10th. Royal Bank Of Canada dropped their price objective on shares of Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating for the company in a research report on Tuesday, November 10th. UBS Group started coverage on shares of Ionis Pharmaceuticals in a research report on Thursday, October 15th. They set a “buy” rating and a $88.00 price target for the company. Wall Street Zen raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. Finally, The Goldman Sachs Group lowered their target price on Ionis Pharmaceuticals from $58.00 to $41.00 and set a “neutral” rating for the company in a report on Tuesday, November 10th. Nineteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.
Check Out Our Latest Report on Ionis Pharmaceuticals
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
See Also
- Five stocks we like better than Ionis Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
